Overview
Aged garlic extract (AGE) is produced by prolonged cold aging of raw garlic in aqueous ethanol, a process that converts unstable, odorous sulfur compounds (including allicin) into stable, bioavailable organosulfur compounds — primarily S-allylcysteine (SAC) and S-allylmercaptocysteine (SAMC). This aging process eliminates the harsh odor and gastrointestinal irritation associated with raw garlic while concentrating and stabilizing its most therapeutically active constituents.
AGE has one of the most robust evidence bases of any botanical cardiovascular supplement, with over 700 peer-reviewed publications and multiple randomized controlled trials demonstrating benefits for blood pressure, lipid profiles, arterial stiffness, platelet function, and atherosclerosis progression. It is a cornerstone of integrative cardiovascular protocols.
Root Causes Addressed by Aged Garlic Extract
1. Hypertension & Endothelial Dysfunction
Elevated blood pressure driven by endothelial dysfunction, reduced nitric oxide (NO) bioavailability, oxidative stress, and vascular inflammation is a primary indication for AGE. Root causes include chronic stress, insulin resistance, high sodium intake, sedentary lifestyle, magnesium deficiency, and aging-related arterial stiffening.
2. Dyslipidemia
AGE modestly reduces total cholesterol and LDL while reducing LDL oxidation — addressing both the quantity and quality of circulating lipoproteins. It is most useful as part of a comprehensive lipid-modulating stack rather than as a standalone cholesterol-lowering agent.
3. Atherosclerosis & Arterial Calcification
AGE has demonstrated the ability to slow atherosclerosis progression and reduce coronary artery calcium (CAC) scores in clinical trials — a direct measure of plaque burden. This makes it one of the few supplements with evidence for actual plaque regression or stabilization.
4. Platelet Hyperaggregability & Thrombotic Risk
Elevated platelet aggregation and fibrinogen levels increase thrombotic cardiovascular risk. AGE reduces platelet aggregation, adhesion, and fibrinogen levels through multiple mechanisms, contributing to antithrombotic cardiovascular protection.
5. Oxidative Stress & Systemic Inflammation
Chronic oxidative stress and low-grade inflammation are upstream drivers of cardiovascular disease, metabolic syndrome, and accelerated aging. AGE's potent antioxidant and anti-inflammatory activity addresses these root causes directly.
Mechanisms of Action
1. Nitric Oxide Enhancement & Vasodilation
S-allylcysteine (SAC) and other AGE organosulfur compounds stimulate endothelial nitric oxide synthase (eNOS), increasing NO production. NO is the primary endogenous vasodilator — it relaxes vascular smooth muscle, reduces peripheral resistance, and lowers blood pressure. AGE also reduces NO degradation by scavenging superoxide radicals that would otherwise inactivate NO.
2. Antioxidant Activity
AGE is a potent antioxidant through multiple mechanisms: direct free radical scavenging by SAC and SAMC, upregulation of endogenous antioxidant enzymes (superoxide dismutase, catalase, glutathione peroxidase), and inhibition of lipid peroxidation. This antioxidant activity protects LDL from oxidative modification — a critical step in atherosclerotic plaque initiation.
3. HMG-CoA Reductase Inhibition
AGE organosulfur compounds modestly inhibit HMG-CoA reductase (the same enzyme targeted by statins), reducing hepatic cholesterol synthesis. This mechanism contributes to the modest LDL-lowering effect observed in clinical trials (typically 5–10% reduction).
4. Antiplatelet & Antithrombotic Effects
AGE reduces platelet aggregation by inhibiting thromboxane A2 (TXA2) synthesis, reducing platelet-activating factor (PAF) activity, and modulating platelet membrane phospholipid composition. It also reduces fibrinogen levels, lowering whole-blood viscosity and thrombotic risk.
5. Anti-Inflammatory Activity
AGE suppresses NF-κB activation, reducing transcription of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α). It also inhibits COX-2 expression and reduces C-reactive protein (CRP) levels in clinical studies. This anti-inflammatory activity contributes to plaque stabilization and reduced cardiovascular event risk.
6. Arterial Stiffness Reduction
Clinical trials using pulse wave velocity (PWV) — the gold standard measure of arterial stiffness — have demonstrated that AGE supplementation significantly reduces arterial stiffness over 12–24 weeks. Reduced arterial stiffness lowers systolic blood pressure and cardiac afterload, reducing cardiovascular risk independent of lipid effects.
7. Coronary Artery Calcium Regression
A landmark randomized controlled trial (Budoff et al., 2016) demonstrated that AGE combined with CoQ10 significantly slowed the progression of coronary artery calcium (CAC) scores compared to placebo over 12 months — one of the few supplement interventions to demonstrate measurable effects on atherosclerotic plaque burden.
Key Takeaways
- Aged garlic extract is one of the most evidence-based botanical cardiovascular supplements, with 700+ publications and multiple RCTs
- Primary mechanisms: eNOS activation and NO enhancement, antioxidant protection of LDL, antiplatelet activity, anti-inflammatory NF-κB suppression, and modest HMG-CoA reductase inhibition
- Clinical evidence supports blood pressure reduction (5–10 mmHg systolic), modest LDL lowering, reduced arterial stiffness, and slowed CAC progression
- S-allylcysteine (SAC) is the primary bioactive — standardized AGE products should specify SAC content
- Odorless and well-tolerated — superior GI tolerability compared to raw garlic
- Synergizes with CoQ10, omega-3s, nattokinase, and magnesium in comprehensive cardiovascular protocols
- Mild antiplatelet effect — use caution with anticoagulants; generally safe at standard doses
Integrative Protocols
Blood Pressure Support Protocol
- Aged garlic extract: 600–1,200 mg/day (standardized to SAC content, e.g., Kyolic brand)
- Combine with magnesium glycinate (400–600 mg/day), potassium (from dietary sources or supplement), and CoQ10 (100–200 mg/day)
- Dietary: DASH-style diet, reduce sodium, increase potassium-rich vegetables
- Monitor blood pressure at baseline and 8–12 weeks
Atherosclerosis & CAC Reduction Protocol
- AGE 1,200 mg/day + CoQ10 (ubiquinol) 200 mg/day — the combination used in the Budoff RCT
- Add omega-3 (EPA+DHA 2–3 g/day) and nattokinase (100–200 mg/day) for comprehensive plaque and fibrinolytic support
- Vitamin K2 (MK-7, 100–200 mcg/day) to direct calcium away from arteries
- Baseline and annual CAC scoring to track progression
Comprehensive Cardiovascular Risk Reduction Stack
- AGE 600–1,200 mg/day
- Omega-3 (EPA+DHA) 2–3 g/day
- CoQ10 (ubiquinol) 100–200 mg/day
- Berberine 500 mg 2–3x/day
- Pantethine 900 mg/day
- Nattokinase 100–200 mg/day
- Monitor lipid panel, hs-CRP, blood pressure, and fasting glucose quarterly
Antiplatelet & Antithrombotic Support
- AGE 600–1,200 mg/day + omega-3 2 g/day + nattokinase 100–200 mg/day
- Use caution and inform prescribing physician if patient is on anticoagulants (warfarin, apixaban) or antiplatelet drugs (aspirin, clopidogrel)
Monitoring
- Blood pressure (home monitoring and clinical) at baseline and 8–12 weeks
- Fasting lipid panel and hs-CRP at baseline and 12–16 weeks
- CAC score (CT calcium scoring) for atherosclerosis tracking — annually or biannually
- Platelet function or INR if on anticoagulant therapy
0 comments